Semaglutide

: Obesity has a huge impact on global healthcare and economy. Consequently, the pharmaceutical industry has recently introduced novel anti-obesity drugs such as semaglutide and tirzepatide, which can yield remarkable weight reduction in patients, whi…

INTRODUCTION: Obesity is increasingly prevalent in type 1 diabetes (T1D), contributing to insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD). While semaglutide has demonstrated weight loss, improved glycemic contr…

BACKGROUND: Body contouring surgery (BCS) addresses excess skin following significant weight loss. While bariatric surgery has been the primary intervention for massive weight loss, the rise of GLP-1 receptor agonists (GLP-1 RAs) introduces a new pat…

AIMS/HYPOTHESIS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally and is closely associated with type 2 diabetes (T2D) and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1R…

Whether the risk of gastric neoplasm is modified by newer glucose-lowering therapies-dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP1RAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2is)-remains unce…

STUDY QUESTION: What is the association between periconceptional GLP-1 receptor agonist exposure and risk of obstetric complications? SUMMARY ANSWER: Periconceptional GLP-1 receptor agonist exposure was associated with increased preterm birth risk wh…

Obesity and hypertension are interdependent chronic conditions that substantially elevate global cardiovascular risk. Rising obesity prevalence has led to a parallel increase in hypertension, driven by complex physiological disturbances that extend b…

INTRODUCTION: Once-weekly semaglutide has proven to be a safe and effective treatment for type 2 diabetes; however, clinical trial data on Asian populations are limited, warranting real-world data (RWD). In this study we assessed the effectiveness an…

BACKGROUND & AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of type 2 diabetes mellitus and obesity in recent years. While gastrointestinal adverse events are common, their association with nutritional d…

AIMS: Glucagon-like peptide-1 receptor agonism (GLP1RA)-based therapies (GLP1RA-BTs) form the cornerstone for managing type 2 diabetes (T2D) and obesity. However, their impact on limb-specific outcomes in peripheral artery disease (PAD) remains uncle…

Limited available data indicate that glucagon-like peptide-1 (GLP-1) medications may significantly reduce weight and binge-eating symptoms among patients with binge-eating disorder. However, experts express concern about the potential for GLP-1 medic…

GLP-1 receptor agonist (GLP-1RA) discontinuation has been associated with weight regain. However, weight trajectories following the last documented GLP-1RA prescription in the real-world clinical setting have not been explored. Here, we assessed weig…

Metabolic dysfunction-associated steatotic liver disease (MASLD), a leading global cause of chronic liver disease, encompasses a wide spectrum of disease stages from isolated hepatic steatosis to cirrhosis. After decades of limited therapeutic option…

IMPORTANCE: The primary analysis of the SELECT randomized clinical trial suggests that semaglutide reduced the rates of cardiovascular (CV) death, myocardial infarction, and stroke in patients with established CV disease (CVD) and overweight or obesi…

PURPOSE OF REVIEW: This review evaluates the antihypertensive potential of next-generation incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists. It examines their effects on blood pressure reduction, underl…

Obesity remains a critical global health challenge, with rising prevalence and a substantial cardiometabolic and psychosocial burden. Recent therapeutic advances, particularly in incretin-based strategies, underscore the need for a comprehensive char…